Company Overview and News

Abbott Laboratories' (ABT) CEO Miles White on Q1 2018 Results - Earnings Call Transcript

17h seekingalpha
Welcome to Abbott’s First Quarter 2018 Earnings Conference Call. All participants will be able to listen only until the question and answer portion of this call. [Operator Instructions] This call is being recorded by Abbott.

Abbott Laboratories Stock Slips Despite Earnings Beat

18h investorplace
Abbott Laboratories (NYSE:ABT) stock as down today despite reporting an earnings beat for the first quarter of 2018.

Abbott sticks to earlier forecasts, disappoints investors

19h channelnewsasia
Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

Abbott (ABT) Beats on Earnings and Revenues in Q1

21h zacks
Abbott Laboratories (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.

Abbott's quarterly profit, sales beat Street estimates - Channel NewsAsia

23h channelnewsasia
Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

Abbott Labs' quarterly revenue rises 16.7 percent

23h channelnewsasia
Abbott Laboratories on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

23h globenewswire
WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment of Susan Washer to its Board of Directors.

Abbott Labs' quarterly revenue rises 16.7 percent

23h reuters
(Reuters) - Abbott Laboratories (ABT.N) on Wednesday posted a 16.7 percent rise in quarterly revenue, helped by strong demand for its newer devices.

Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications

2018-04-17 globenewswire
NEWARK, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced the appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications, effective immediately.

Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?

2018-04-17 zacks
Varian Medical Systems Inc. (VAR - Free Report) is scheduled to report second-quarter fiscal 2018 earnings on Apr 26, after the market closes. Favorable revenue opportunity from its various Oncology and Imaging Component products, growing adoption of Proton Therapy and strong overseas presence are likely to drive the company’s second-quarter fiscal 2018 earnings.

Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?

2018-04-17 zacks
Baxter International Inc. (BAX - Free Report) is scheduled to report first-quarter 2018 earnings on Apr 26, before the market opens. Positive tidings on the regulatory front, expanding product portfolio, strategic collaborations and strong presence in the international markets are key positives at the moment.

Will Core Segmental Growth Aid Stryker (SYK) in Q1 Earnings?

2018-04-16 zacks
Stryker Corporation’s (SYK - Free Report) first-quarter 2018 results are scheduled for release on Apr 26, after market close. The company’s acquisition-driven strategy is expected to boost growth by expanding existing product offerings in all business segments.

Can Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?

2018-04-16 zacks
Intuitive Surgical Inc.’s (ISRG - Free Report) first-quarter 2018 results, expected to release on Apr 17 after market close, are expected to show steady growth in the instruments and accessories segment.

SA Stock To Watch: Netflix To The Rescue?

2018-04-14 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 002824100